Forum Financial Management LP Has $790,000 Stock Position in Becton, Dickinson and Company $BDX

Forum Financial Management LP grew its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 19.1% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,589 shares of the medical instruments supplier’s stock after buying an additional 736 shares during the quarter. Forum Financial Management LP’s holdings in Becton, Dickinson and Company were worth $790,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the business. Northcape Wealth Management LLC grew its holdings in shares of Becton, Dickinson and Company by 0.5% during the first quarter. Northcape Wealth Management LLC now owns 9,814 shares of the medical instruments supplier’s stock valued at $2,248,000 after buying an additional 51 shares during the last quarter. Diversified Trust Co grew its holdings in shares of Becton, Dickinson and Company by 4.7% during the first quarter. Diversified Trust Co now owns 1,188 shares of the medical instruments supplier’s stock valued at $272,000 after buying an additional 53 shares during the last quarter. Bill Few Associates Inc. boosted its holdings in Becton, Dickinson and Company by 0.7% during the second quarter. Bill Few Associates Inc. now owns 7,906 shares of the medical instruments supplier’s stock worth $1,362,000 after purchasing an additional 55 shares during the last quarter. Meadow Creek Wealth Advisors LLC boosted its holdings in Becton, Dickinson and Company by 5.4% during the first quarter. Meadow Creek Wealth Advisors LLC now owns 1,161 shares of the medical instruments supplier’s stock worth $266,000 after purchasing an additional 59 shares during the last quarter. Finally, Stephens Inc. AR grew its position in Becton, Dickinson and Company by 0.3% in the 1st quarter. Stephens Inc. AR now owns 18,578 shares of the medical instruments supplier’s stock worth $4,255,000 after purchasing an additional 59 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

BDX has been the subject of a number of recent analyst reports. Wells Fargo & Company upped their price objective on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a research report on Friday, August 8th. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $211.00 price objective on shares of Becton, Dickinson and Company in a research report on Thursday, October 16th. Argus upped their price objective on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Wall Street Zen raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Wednesday, October 8th. Three investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $205.40.

Becton, Dickinson and Company Stock Down 0.8%

BDX opened at $186.62 on Friday. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. The stock has a market cap of $53.49 billion, a price-to-earnings ratio of 33.56, a PEG ratio of 1.47 and a beta of 0.25. Becton, Dickinson and Company has a twelve month low of $163.33 and a twelve month high of $251.99. The company’s 50-day moving average price is $190.13 and its two-hundred day moving average price is $184.19.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. The firm had revenue of $5.32 billion for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. As a group, equities analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, Director Claire Fraser sold 917 shares of the business’s stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the transaction, the director directly owned 22,226 shares in the company, valued at $4,167,375. The trade was a 3.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 1,838 shares of company stock valued at $348,392 in the last 90 days. 0.36% of the stock is owned by insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.